Ari Maizel's most recent trade in Axsome Therapeutics Inc was a trade of 7,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 22, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 7,500 | 23,710 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.73 per share. | 22 Apr 2026 | 7,500 | 7,500 (0%) | 0% | 70.7 | 530,475 | Common Stock |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 182.42 per share. | 22 Apr 2026 | 7,500 | 0 (0%) | 0% | 182.4 | 1,368,150 | Common Stock |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2026 | 7,224 | 7,224 | - | - | Performance Stock Units | |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 16,385 | 16,385 | - | - | Restricted Stock Units | |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.73 per share. | 21 Jan 2026 | 7,500 | 7,500 (0%) | 0% | 70.7 | 530,475 | Common Stock |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 184.44 per share. | 21 Jan 2026 | 7,500 | 0 (0%) | 0% | 184.4 | 1,383,300 | Common Stock |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2026 | 7,500 | 31,210 | - | - | Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 7,816 | 7,816 | - | - | Employee Stock Option (Right to Buy) | |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 7,740 | 7,740 | - | - | Performance Stock Units | |
| Axsome Therapeutics Inc | Ari Maizel | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 7,740 | 7,740 | - | - | Restricted Stock Units |